TFF Pharmaceuticals, Inc. (TFFP)
| Previous Close | 7.52 |
| Open | 7.59 |
| Bid | 7.48 x 800 |
| Ask | 7.84 x 4000 |
| Day's Range | 7.27 - 7.66 |
| 52 Week Range | 6.85 - 21.14 |
| Volume | 86,234 |
| Avg. Volume | 156,531 |
| Market Cap | 191.754M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.60 |
| Earnings Date | May 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- Simply Wall St.
Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load
Results published in bioRxiv Show That Delivery of Dry Powder AUG-3387 Following Viral Inoculation Led to Dose-Dependent Reduction in Lung Viral Load in Hamsters Dry Powder Formulations Show Equivalent Binding as Original Antibody with No Loss of Biologic Activity Study Indicates AUG-3387 Binds to Both Lambda and Mu Variants of SARS-CoV-2 AUSTIN, Texas and MENLO PARK, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company fo
- GlobeNewswire
TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation
Inhaled Tacrolimus Shows Dose-Dependent PK that Achieves Desired Therapeutic Plasma Concentrations and Promising Safety Profile in both SAD and MAD Components of Phase 1AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced topline results from the recently completed P
